Bio-Nanoparticles for HIV Antigen Delivery

描述（由申请人提供）：一种有效的HIV-1疫苗可能需要ctl诱导成分。迄今为止，只有重组腺病毒-5疫苗是这种成分的候选物，但它面临着载体免疫的重大问题，并且对粘膜组织的进入能力未知。纳米粒子作为疫苗载体具有一定的优势，但也面临着免疫原性、致癌性和制造质量等问题。

DESCRIPTION (provided by applicant): It is likely that a CTL-eliciting component will be required for an effective HIV-1 vaccine. To date, only the recombinant adenovirus-5 vaccine has been a candidate for such a component, but it faced significant issues with vector immunity and had unknown capacity to access mucosal tissues. Nanoparticles offer some advantages as vaccine vectors, but face problems with immunogenicity, carcinogenicity, and manufacturing quality. This proposal explores the use of biological nanoparticles ("vaults") composed of autologous human proteins, loaded with HIV-1 sequences to serve as a vaccine. Vaults have been shown to be immunogenic for CTL responses and access the mucosal immune system. Additionally, they are composed of self-proteins that are normally found in the cytoplasm and therefore should not be immunogenic or carcinogenic, and are readily manufactured with consistent quality. The two aims will be: Aim 1: To create targeted vaults carrying conserved HIV-1 protein sequences; Aim 2: To confirm the immunogenicity of the vaults in systemic and mucosal immune compartments.